Cryo Cell International (CCEL) Liabilities and Shareholders Equity (2010 - 2026)

Cryo Cell International (CCEL) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $60.9 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $60.9 million, down 5.43% year-over-year; the trailing twelve-month figure through Feb 2026 was $250.2 million (down 1.7% YoY), and the FY2025 annual result was $61.7 million, down 4.56% from the prior year.
• Liabilities and Shareholders Equity slipped to $60.9 million in Q1 2026 per CCEL's latest filing, from $61.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $69.8 million in Q3 2023 and troughed at $54.8 million in Q1 2022.
• A 5-year average of $63.4 million and a median of $64.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 440.93% in 2022 and fell as far as 47.93% in 2022.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $64.9 million in 2022, then fell by 0.32% to $64.7 million in 2023, then changed by 0.0% to $64.7 million in 2024, then declined by 4.56% to $61.7 million in 2025, then retreated by 1.37% to $60.9 million in 2026.
• Business Quant data shows CCEL's Liabilities and Shareholders Equity at $60.9 million in Q1 2026, $61.7 million in Q4 2025, and $63.2 million in Q3 2025.